Cite
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
MLA
Takahashi, Koichi, et al. “CCL3 and CCL4 Are Biomarkers for B Cell Receptor Pathway Activation and Prognostic Serum Markers in Diffuse Large B Cell Lymphoma.” British Journal of Haematology, vol. 171, no. 5, Dec. 2015, pp. 726–35. EBSCOhost, https://doi.org/10.1111/bjh.13659.
APA
Takahashi, K., Sivina, M., Hoellenriegel, J., Oki, Y., Hagemeister, F. B., Fayad, L., Romaguera, J. E., Fowler, N., Fanale, M. A., Kwak, L. W., Samaniego, F., Neelapu, S., Xiao, L., Huang, X., Kantarjian, H., Keating, M. J., Wierda, W., Fu, K., Chan, W. C., & Vose, J. M. (2015). CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology, 171(5), 726–735. https://doi.org/10.1111/bjh.13659
Chicago
Takahashi, Koichi, Mariela Sivina, Julia Hoellenriegel, Yasuhiro Oki, Fredrick B. Hagemeister, Luis Fayad, Jorge E. Romaguera, et al. 2015. “CCL3 and CCL4 Are Biomarkers for B Cell Receptor Pathway Activation and Prognostic Serum Markers in Diffuse Large B Cell Lymphoma.” British Journal of Haematology 171 (5): 726–35. doi:10.1111/bjh.13659.